{
  "id": "c-peptide",
  "title": "C-Peptide",
  "lang": "en",
  "source_lang": "en",
  "summary": "C-peptide is a peptide released with insulin by pancreatic beta cells and measured as an indicator of the body’s own insulin production.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "Connecting peptide",
    "Insulin C-peptide"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/c-peptide/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/c-peptide/",
      "json": "https://aiwiki.page/zh/c-peptide.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "C-peptide is a 31-amino-acid peptide released into the bloodstream when proinsulin is processed into mature insulin. It is produced by the beta cells of the pancreas and secreted in approximately equal molar amounts with insulin. Because injected insulin does not contain C-peptide, its measurement provides information about endogenous insulin secretion—the insulin produced by the body itself."
    },
    {
      "heading": "Formation and secretion",
      "text": "Insulin is initially synthesized as preproinsulin, a precursor containing a signal peptide that directs it into the endoplasmic reticulum. Removal of the signal peptide produces proinsulin, in which the future insulin B and A chains are joined by the connecting peptide.\n\nThis connecting segment helps the precursor adopt the structure required for correct folding and formation of insulin’s disulfide bonds. During maturation in secretory granules, enzymes cleave proinsulin at the boundaries of the connecting segment and remove residual basic amino acids. The resulting products are mature insulin and free C-peptide.\n\nWhen beta cells respond to stimuli such as an increase in blood glucose, secretory granules release both products. Although insulin and C-peptide are released in approximately equimolar amounts, their concentrations in peripheral blood are not equal because their clearance differs."
    },
    {
      "heading": "Circulation and clearance",
      "text": "A substantial proportion of newly secreted insulin is removed by the liver before reaching the general circulation. C-peptide undergoes comparatively little hepatic extraction and is cleared largely through the kidneys.\n\nC-peptide has a circulating half-life of roughly 20–30 minutes, compared with approximately 3–5 minutes for insulin. Consequently, its blood concentration is usually higher and varies less rapidly than that of insulin. These properties make it useful for assessing insulin secretion, although a single concentration is not a direct measurement of the instantaneous secretion rate.\n\nReduced kidney function can raise circulating C-peptide by decreasing its clearance. This is an important limitation when interpreting results."
    },
    {
      "heading": "Measurement",
      "text": "C-peptide is commonly measured in serum or plasma using an immunoassay. Urinary measurements, including the urine C-peptide-to-creatinine ratio, are also used in some settings.\n\nBlood samples may be obtained during fasting, after a meal, or during a standardized stimulation test. These conditions assess different aspects of beta-cell function and do not have interchangeable reference ranges. A stimulated measurement evaluates the response to a defined stimulus, whereas a fasting measurement reflects secretion under fasting conditions.\n\nResults may be expressed in nanomoles per litre or nanograms per millilitre. For human C-peptide:\n\n\\[1\\ \\text{ng/mL} \\approx 0.331\\ \\text{nmol/L}.\\]\n\nInterpretation depends on the concurrent glucose concentration, sampling conditions, kidney function, and the assay used. Low glucose normally suppresses insulin and C-peptide secretion, so a low concentration during hypoglycemia has a different meaning from the same concentration during hyperglycemia. Assay interference and differences between laboratory methods can also affect results."
    },
    {
      "heading": "Clinical uses",
      "text": "Assessment of endogenous insulin secretion\n\nC-peptide helps characterize residual beta-cell function in diabetes mellitus, including in people receiving injected insulin.\n\nVery low or undetectable concentrations can indicate severe endogenous insulin deficiency. Detectable secretion may persist in type 1 diabetes, however, and reduced secretion can occur in longstanding type 2 diabetes. C-peptide therefore does not, by itself, establish diabetes type. Clinical history, glucose measurements, and, where relevant, autoantibody testing provide complementary information.\n\nHigher concentrations may accompany increased insulin secretion associated with insulin resistance, but can also reflect reduced renal clearance.\n\nInvestigation of hypoglycemia\n\nC-peptide is one component of the biochemical investigation of hypoglycemia. During a documented episode, its relationship to insulin and glucose can help distinguish possible mechanisms.\n\nInsulin administered from outside the body can produce high insulin with suppressed C-peptide. Endogenous insulin secretion can produce insulin and C-peptide concentrations that are inappropriately elevated for the low glucose level. This pattern can occur with an insulin-secreting tumour or exposure to medicines that stimulate insulin secretion. Distinguishing these causes requires additional laboratory and clinical information.\n\nResearch\n\nC-peptide measurements are widely used as outcomes in studies of beta-cell preservation, pancreatic islet transplantation, and diabetes progression. Repeated measurements during standardized tests can also support mathematical estimates of insulin secretion rates."
    },
    {
      "heading": "Biological activity",
      "text": "C-peptide’s established physiological role is as the connecting segment within proinsulin during insulin maturation. Experimental studies have also investigated possible effects of free C-peptide on cellular signalling, blood flow, and nerve and kidney function. These findings have not established C-peptide replacement as a routine clinical treatment. Its principal established medical use remains the assessment of endogenous insulin secretion."
    }
  ],
  "links": [
    "amino-acid",
    "insulin",
    "endoplasmic-reticulum",
    "protein-folding",
    "enzyme",
    "glucose",
    "half-life",
    "diabetes-mellitus",
    "autoantibody",
    "hypoglycemia"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}